BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
By API User
Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne to participate in Project Orbis program, supporting efforts to rapidly advance global access SAN CARLOS, Calif.–BUSINESS WIRE– BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, … Continued